The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

Video

Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.

Related Videos
blur image background of corridor in hospital or clinic image | Image Credit @ whyframeshot - stock.adobe.com
Dr. Mehmet Asim Bilen in an interview with Urology Times
blurred clinic hallway
Dr. Adam Weiner in an interview with Urology Times
Dr. Sagar Patel in an interview with Urology Times
Related Content
© 2024 MJH Life Sciences

All rights reserved.